公开(公告)号：US20220257607A1

公开(公告)日：2022-08-18

申请号：US17629824

申请日：2020-04-23

Applicant: Amgen Inc.

Inventor： Ron C. KELLY ,  Michael T. KENNEDY ,  Stevedat K. LA

IPC: A61K31/553 ,  A61K47/69 ,  A61K47/18 ,  A61K47/02 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02

Abstract: Formulations of compounds of Formula I are provided as are doses and dosing regimens useful in methods of treating cancer including hematological malignances such as acute myelogenous leukemia, multiple myeloma, and non-Hodgkin's lymphoma.

公开(公告)号：US20180161279A1

公开(公告)日：2018-06-14

申请号：US15840908

申请日：2017-12-13

Applicant: AMGEN INC.

Inventor： John Inn CHUNG ,  Armen PIRJANIAN ,  Fernando Antonio ALVAREZ-NUNEZ ,  Jeffrey Michael KATZ ,  Dominick Paul DAURIO ,  Stevedat LA ,  Michael T. KENNEDY

IPC: A61K9/20 ,  A61K9/00 ,  A61K9/28 ,  A61K38/06

CPC classification number: A61K9/2031 ,  A61K9/0065 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/28 ,  A61K38/06

Abstract: This disclosure features gastro-retentive (GR) modified release pharmaceutical dosage forms (e.g., solid dosage forms, e.g., tablets, e.g., bilayer tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the dosage form.